201 related articles for article (PubMed ID: 37499518)
41. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
[TBL] [Abstract][Full Text] [Related]
42. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
[TBL] [Abstract][Full Text] [Related]
43. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
[No Abstract] [Full Text] [Related]
44. Role of miRNAs in endometrial cancer.
Li S; Zhang J; Wan X
Histol Histopathol; 2015 May; 30(5):539-48. PubMed ID: 25448606
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.
Zhang X; Chen Y; Zhao P; Zang L; Zhang Z; Wang X
Leuk Lymphoma; 2017 Apr; 58(4):932-940. PubMed ID: 27830963
[TBL] [Abstract][Full Text] [Related]
46. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA theragnostics for the clinical management of multiple myeloma.
Ahmad N; Haider S; Jagannathan S; Anaissie E; Driscoll JJ
Leukemia; 2014 Apr; 28(4):732-8. PubMed ID: 24714346
[TBL] [Abstract][Full Text] [Related]
48. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
49. MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review).
Hu M; Zhu S; Xiong S; Xue X; Zhou X
Oncol Rep; 2019 Mar; 41(3):1439-1454. PubMed ID: 30628706
[TBL] [Abstract][Full Text] [Related]
50. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
51. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
52. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
53. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.
Chen H; Cao W; Chen J; Liu D; Zhou L; Du F; Zhu F
J Cell Biochem; 2021 Apr; 122(3-4):305-314. PubMed ID: 33417267
[TBL] [Abstract][Full Text] [Related]
54. miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.
Seckinger A; Meißner T; Moreaux J; Benes V; Hillengass J; Castoldi M; Zimmermann J; Ho AD; Jauch A; Goldschmidt H; Klein B; Hose D
Oncotarget; 2015 Nov; 6(36):39165-83. PubMed ID: 26472281
[TBL] [Abstract][Full Text] [Related]
55. Long noncoding RNA H19 promotes vincristine resistance in multiple myeloma by targeting Akt.
Wang Y; Xu S; Wang L; Liu J; Wang J; Zhou J
Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):76-80. PubMed ID: 33040789
[TBL] [Abstract][Full Text] [Related]
56. Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background.
Papanota AM; Karousi P; Kontos CK; Ntanasis-Stathopoulos I; Scorilas A; Terpos E
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673480
[TBL] [Abstract][Full Text] [Related]
57. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
Gasparri ML; Besharat ZM; Farooqi AA; Khalid S; Taghavi K; Besharat RA; Sabato C; Papadia A; Panici PB; Mueller MD; Ferretti E
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2313-2318. PubMed ID: 30109500
[TBL] [Abstract][Full Text] [Related]
58. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
[TBL] [Abstract][Full Text] [Related]
59. Identification of long noncoding RNA
Chen T; Sun Z; Cui Y; Ji J; Li Y; Qu X
Hematology; 2023 Dec; 28(1):2164449. PubMed ID: 36657019
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Amodio N; Stamato MA; Gullà AM; Morelli E; Romeo E; Raimondi L; Pitari MR; Ferrandino I; Misso G; Caraglia M; Perrotta I; Neri A; Fulciniti M; Rolfo C; Anderson KC; Munshi NC; Tagliaferri P; Tassone P
Mol Cancer Ther; 2016 Jun; 15(6):1364-75. PubMed ID: 27196750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
